Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160897 | 0.84 | HCRTR2 (0.33) | HCRTR2SMN1; SMN2CMA1HRH3KMT2A | |
| SCHEMBL5160189 | 0.82 | FKBP1A (0.46) | KMT2A | |
| SCHEMBL5160346 | 0.80 | MEN1 (0.33) | KMT2A | |
| SCHEMBL5409090 | 0.78 | EPHX1 (0.37) | SMN1; SMN2KMT2A | |
| SCHEMBL5161584 | 0.75 | HSD17B10 (0.39) | SMN1; SMN2HRH3KMT2APOLB | |
| SCHEMBL5158933 | 0.74 | HRH3 (0.33) | HCRTR2SMN1; SMN2CMA1HRH3 | |
| SCHEMBL5163237 | 0.74 | RAB9A (0.40) | HCRTR2KMT2APOLB | |
| SCHEMBL6179708 | 0.72 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2APOLB | |
| SCHEMBL5161578 | 0.72 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2APOLB | |
| SCHEMBL5160904 | 0.68 | SMN1; SMN2 (0.34) | SMN1; SMN2CMA1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | HCRTR2 4475/4885SMN1; SMN2 3016/4885CMA1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.